Hester Biosciences Limited
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- ₹14.12 billion
- Book Value:
- Revenue TTM:
- ₹2.81 billion
- Operating Margin TTM:
- Gross Profit TTM:
- ₹1.68 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Hester Biosciences Limited had its IPO on under the ticker symbol HESTERBIO.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Hester Biosciences Limited has a staff strength of 0 employees.
Shares of Hester Biosciences Limited opened at ₹1647.1 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of ₹1647.1 - ₹1672.05, and closed at ₹1656.9.
This is a -0.41% slip from the previous day's closing price.
A total volume of 1,309 shares were traded at the close of the day’s session.
In the last one week, shares of Hester Biosciences Limited have slipped by -4.75%.
Hester Biosciences Limited's Key Ratios
Hester Biosciences Limited has a market cap of ₹14.12 billion, indicating a price to book ratio of 5.8729 and a price to sales ratio of 6.6683.
In the last 12-months Hester Biosciences Limited’s revenue was ₹2.81 billion with a gross profit of ₹1.68 billion and an EBITDA of ₹657.60 million. The EBITDA ratio measures Hester Biosciences Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Hester Biosciences Limited’s operating margin was 16.02% while its return on assets stood at 4.57% with a return of equity of 10.09%.
In Q1, Hester Biosciences Limited’s quarterly earnings growth was a negative -36.5% while revenue growth was a positive 14.5%.
Hester Biosciences Limited’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹33.02 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Hester Biosciences Limited’s profitability.
Hester Biosciences Limited stock is trading at a EV to sales ratio of 7.5614 and a EV to EBITDA ratio of 27.8219. Its price to sales ratio in the trailing 12-months stood at 6.6683.
Hester Biosciences Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0.6% and a payout ratio of 38.5%.
Balance sheet and cash flow metrics
- Total Assets
- ₹5.46 billion
- Total Liabilities
- ₹1.36 billion
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Hester Biosciences Limited ended 2023 with ₹5.46 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹5.46 billion while shareholder equity stood at ₹2.92 billion.
Hester Biosciences Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹1.36 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹43.01 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹833.97 million.
Hester Biosciences Limited’s total current assets stands at ₹2.16 billion while long-term investments were ₹0 and short-term investments were ₹183.07 million. Its net receivables were ₹823.60 million compared to accounts payable of ₹287.11 million and inventory worth ₹792.16 million.
In 2023, Hester Biosciences Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Hester Biosciences Limited paid ₹0.39 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Hester Biosciences Limited stock is currently trading at ₹1656.9 per share. It touched a 52-week high of ₹2439.3088 and a 52-week low of ₹2439.3088. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹1729.08 and 200-day moving average was ₹1882.56 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6337.4% of the company’s stock are held by insiders while 44.2% are held by institutions.
Frequently Asked Questions About Hester Biosciences Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates in two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for diseases, such as newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reo, marek’s disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, avian encephalomyelitis, etc. It also offers vaccines for large animals comprising Goat Pox, Peste des Petits Ruminants, Brucellosis, Mastitis, Metritis, and various infectious diseases, as well as infections, reproductive disorders, theileriosis, parasitic diseases, etc. In addition, the company provides feed supplements, such as toxin binder, trace minerals, enzyme preparation, and bypass fat; disinfectants for farms and equipment, and water sanitizers; nutrition products consisting of mineral mixtures, fertility supplements, and growth tonics; and herbal products, including growth promoters, herbal replacers for choline chloride, stress relievers and immunity boosters, respiratory stimulants, liver tonics, wound healing preparations, uterine tonics, digestive tonics and anti-bloat solutions, ectoparasiticide preparations, anti-mastitis, and anti-prolapse preparations. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Ahmedabad, India.